Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has issued an announcement.
Zhaoke Ophthalmology has renewed its contract manufacturing arrangement with related party Lee’s Pharm Hefei to secure continued production of its ophthalmic drug Eyprotor for commercial sale. The deal is structured through a supplemental agreement extending the existing master CMO service agreement via its subsidiary Zhaoke Guangzhou.
The renewed agreement runs for three years from the end of 2025 to December 31, 2028, with an automatic three-year extension unless either party objects in writing. Pricing will continue to be based on estimated manufacturing cost plus a gross profit margin of about 70%, which an independent consultancy has assessed as consistent with prevailing market levels.
Under Hong Kong listing rules, the renewed transactions qualify as continuing connected transactions because Lee’s Pharm is a substantial shareholder, triggering reporting and announcement obligations. However, the relevant percentage ratios remain below 5%, so the arrangement is exempt from circular and independent shareholder approval requirements, simplifying execution for the company.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a Hong Kong-listed ophthalmic pharmaceutical company focused on developing and commercializing treatments for eye diseases. Through its subsidiary Zhaoke Guangzhou, the company engages in manufacturing partnerships and contract production arrangements to support the commercial supply of its ophthalmic products, including Eyprotor, for targeted markets.
Average Trading Volume: 532,834
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.65B
See more data about 6622 stock on TipRanks’ Stock Analysis page.